Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Details

announced the early release of late-breaking abstracts for presentation at the Endocrine Society's annual meeting, ENDO 2024. These abstracts include data from a Phase 2 study of atumelnant (CRN04894) in Congenital Adrenal Hyperplasia. The more comprehensive data set, including results from six subjects in cohort 1 and additional subjects in cohort 2, will be presented during the Late-Breaking Poster Presentation session on June 3, 2024.

Items reported

Exhibits (1)

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.